- Clinical Expertise
- Research Faculty
- Cancer Prevention Research
- Board Certifications
- Internal Medicine
- Medical Oncology
- Appointments
- Irving Assistant Professor of Medicine, Columbia University Medical Center
- Education
- B.S., 1986, Massachusetts Institute of Technology, Cambridge, MA
- M.D., 1991, Mount Sinai School of Medicine, New York, NY
- Internship & Residency
- Internal Medicine, 1994, New York-Presbyterian Hospital, New York, NY
- Fellowship
- Oncology, 1999, Columbia University College of Physicians, New York, NY
Andrew Joe, M.D.
TEL (212) 305-6916
FAX (212) 305-6889
- PROFILE SUMMARY
- Andrew K. Joe, M.D. is an Irving Assistant Professor of Clinical Medicine at the College of Physicians and Surgeons, Columbia University Medical Center. Dr. Joe received undergraduate B.S. degrees in Chemistry and Biology from the Massachusetts Institute of Technology and his M.D. degree from Mount Sinai School of Medicine. He completed Internal Medicine training at New York Presbyterian Hospital, Columbia University Medical Center and fellowship training in Medical Oncology at Columbia University. He is currently involved in laboratory and clinical research, teaching, and patient care on the oncology service.
Chemoprevention is the area of cancer prevention in which pharmacological or biological agents are used to inhibit, delay or reverse carcinogenesis. Dr. Joe’s research focuses on evaluating cancer prevention agents in laboratory and clinical models, and in identifying surrogate tumor markers for use in chemoprevention trials. He is conducting translational, patient-oriented projects that include the following: investigation of tumor biomarkers and potential chemoprevention agents in human cancer cell lines; investigation of biomarkers in human blood and tissue specimens using immunohistochemistry, genotyping, and gene microarrays; and design and conduct of early phase chemoprevention trials. He is currently investigating the in vitro and in vivo effects of the green tea-derived catechin mixture, Polyphenon E in human Barrett’s Esophagus-Associated Adenocarcinoma-derived cell lines and in patients with Barrett’s Esophagus. He is also investigating differences in tumor biology in breast cancers that develop in African-American and Caucasian patients.